Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29510942 | 0.84 | ALDH1A1 (0.61) | ALDH1A1RECQLIDO1LMNAGAA | |
| SCHEMBL238824 | 0.84 | ALDH1A1 (0.61) | ALDH1A1RECQLIDO1LMNAGAA | |
| SCHEMBL790910 | 0.82 | CYP1A2 (0.37) | ALDH1A1RECQLLMNAGAAJAK2 | |
| SCHEMBL7821244 | 0.81 | LMNA (0.62) | ALDH1A1RECQLIDO1LMNAGAA | |
| SCHEMBL5168338 | 0.78 | KDM4E (0.40) | ALDH1A1RECQLLMNAGAAJAK2 | |
| SCHEMBL815746 | 0.78 | CYP1A2 (0.47) | ALDH1A1LMNAGAAJAK2MAPT | |
| SCHEMBL10536881 | 0.78 | KDM4E (0.40) | ALDH1A1RECQLLMNAGAAJAK2 | |
| SCHEMBL17478137 | 0.78 | KDM4E (0.40) | ALDH1A1RECQLLMNAGAAJAK2 | |
| SCHEMBL3730684 | 0.78 | KDM4E (0.68) | ALDH1A1LMNAGAAJAK2MAPT | |
| SCHEMBL1938309 | 0.77 | TP53 (0.57) | ALDH1A1RECQLIDO1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569317-B2 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2013-10-29 | — | — | US | disclosed |
| US-7696216-B2 | Aryl-quinazoline/aryl-2-amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20100063075-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | ALTMANN EVA | 2010-03-11 | — | — | US | disclosed |
| EP-1585521-B8 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| EP-1585521-B1 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2008-06-18 | — | — | EP | disclosed |
| EP-1844780-A2 | Derivatives of aryl-quinazoline/aryl-2-amino-phenyl methanone which promote the release of parathyroid hormone | Novartis Pharma AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060079685-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | NOVARTIS AG (CH) | 2006-04-13 | — | — | US | disclosed |
| EP-1585521-A2 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | Novartis AG (CH) | 2005-10-19 | — | — | EP | disclosed |
| WO-2004056365-A2 | DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2AMINO-PHENYL METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID HORMONE | NOVARTIS AG (CH) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079685-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | PTH1R, PTMS, CYP24A1 | ALDH1A1 3159/4885RECQL 813/4885IDO1 3080/4885 |
| US-20100063075-A1 | Aryl-quinazoline/aryl-2amino-phenyl methanone derivatives | PTH1R, PTMS, CYP24A1 | ALDH1A1 3107/4885RECQL 890/4885IDO1 3010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.